Brief: Adagene Announces First Patient Dosed With Novel, Proprietary Combination Of Anti-Cd137 Agonist, Adg106, And Anti-Ctla-4 Monoclonal Antibody, Adg116
27/01/2022 12:54
Jan 27 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES FIRST PATIENT DOSED WITH NOVEL,
PROPRIETARY
COMBINATION OF ANTI-CD137 AGONIST, ADG106, AND ANTI-CTLA-4
MONOCLONAL ANTIBODY, ADG116
Source text for Eikon: ID:nGNX3YT8yB
Further company coverage: 978y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate
Brief: Adagene Inc - Partners With Conjugatebio For Antibody Drug Conjugate Development
Brief: Adagene Announces Up To $25 Million Strategic Investment From Sanofi